Nanocomposites Based on Nanoceria Regulate the Immune Microenvironment for the Treatment of Polycystic Ovary Syndrome

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Nov 7

PMID 37936120

Authors

Sisi Yan

Zhipeng Gao

Jinli Ding

Suming Chen

Zehao Wang

Wenyi Jin

Bing Qu

Yi Zhang

Lian Yang

Duanying Guo

Tailang Yin

Yanbing Yang

Yan Zhang

Jing Yang

Affiliations

Soon will be listed here.

Abstract

The immune system is closely associated with the pathogenesis of polycystic ovary syndrome (PCOS). Macrophages are one of the important immune cell types in the ovarian proinflammatory microenvironment, and ameliorate the inflammatory status mainly through M2 phenotype polarization during PCOS. Current therapeutic approaches lack efficacy and immunomodulatory capacity, and a new therapeutic method is needed to prevent inflammation and alleviate PCOS. Here, octahedral nanoceria nanoparticles with powerful antioxidative ability were bonded to the anti-inflammatory drug resveratrol (CeO@RSV), which demonstrates a crucial strategy that involves anti-inflammatory and antioxidative efficacy, thereby facilitating the proliferation of granulosa cells during PCOS. Notably, our nanoparticles were demonstrated to possess potent therapeutic efficacy via anti-inflammatory activities and effectively alleviated endocrine dysfunction, inflammation and ovarian injury in a dehydroepiandrosterone (DHEA)-induced PCOS mouse model. Collectively, this study revealed the tremendous potential of the newly developed nanoparticles in ameliorating the proinflammatory microenvironment and promoting the function of granulosa cells, representing the first attempt to treat PCOS by using CeO@RSV nanoparticles and providing new insights in combating clinical PCOS.

Citing Articles

Macrophages: a double-edged sword in female reproduction and disorders.

Park M, Kim Y, Song H Exp Mol Med. 2025; 57(2):285-297.

PMID: 39894821 PMC: 11873061. DOI: 10.1038/s12276-025-01392-6.

Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease.

Shi M, Li X, Xing L, Li Z, Zhou S, Wang Z Pharmaceutics. 2025; 16(12.

PMID: 39771535 PMC: 11678845. DOI: 10.3390/pharmaceutics16121556.

Development of machine learning models for diagnostic biomarker identification and immune cell infiltration analysis in PCOS.

Chen W, Miao J, Chen J, Chen J J Ovarian Res. 2025; 18(1):1.

PMID: 39754246 PMC: 11697806. DOI: 10.1186/s13048-024-01583-1.

Cartilage-targeting peptide-modified cerium oxide nanoparticles alleviate oxidative stress and cartilage damage in osteoarthritis.

Zhuang H, Ren X, Li H, Zhang Y, Zhou P J Nanobiotechnology. 2024; 22(1):784.

PMID: 39702137 PMC: 11657866. DOI: 10.1186/s12951-024-03068-1.

Altered Immune Cell Profiles in the Follicular Fluid of Patients with Poor Ovarian Response According to the POSEIDON Criteria.

Zhou L, Zhao S, Luo J, Rao M, Yang S, Wang H J Inflamm Res. 2024; 17:10663-10679.

PMID: 39677298 PMC: 11638477. DOI: 10.2147/JIR.S473068.

References

Liu S, Du Y, Shi K, Yang Y, Yang Z . Resveratrol improves cardiac function by promoting M2-like polarization of macrophages in mice with myocardial infarction. Am J Transl Res. 2019; 11(8):5212-5226. PMC: 6731431. View

Vassie J, Whitelock J, Lord M . Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells. Acta Biomater. 2016; 50:127-141. DOI: 10.1016/j.actbio.2016.12.010. View

Dapas M, Dunaif A . Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. Endocr Rev. 2022; 43(6):927-965. PMC: 9695127. DOI: 10.1210/endrev/bnac001. View

Fu X, Sun Z, Long Q, Tan W, Ding H, Liu X . Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway. Phytomedicine. 2022; 105:154385. DOI: 10.1016/j.phymed.2022.154385. View

Velez L, Seldin M, Motta A . Inflammation and reproductive function in women with polycystic ovary syndrome†. Biol Reprod. 2021; 104(6):1205-1217. PMC: 8785941. DOI: 10.1093/biolre/ioab050. View

Gonzalez F . Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2011; 77(4):300-5. PMC: 3309040. DOI: 10.1016/j.steroids.2011.12.003. View

Lima P, Nivet A, Wang Q, Chen Y, Leader A, Cheung A . Polycystic ovary syndrome: possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages. Biol Reprod. 2018; 99(4):838-852. PMC: 6203875. DOI: 10.1093/biolre/ioy096. View

Yan S, Ding J, Zhang Y, Wang J, Zhang S, Yin T . C1QTNF6 participates in the pathogenesis of PCOS by affecting the inflammatory response of granulosa cells‡. Biol Reprod. 2021; 105(2):427-438. DOI: 10.1093/biolre/ioab094. View

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110(3):364-379. PMC: 6939856. DOI: 10.1016/j.fertnstert.2018.05.004. View

10.

Dumesic D, Oberfield S, Stener-Victorin E, Marshall J, Laven J, Legro R . Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5):487-525. PMC: 4591526. DOI: 10.1210/er.2015-1018. View

11.

Wong D, Villanueva J, Cress A, Duleba A . Effects of resveratrol on proliferation and apoptosis in rat ovarian theca-interstitial cells. Mol Hum Reprod. 2010; 16(4):251-9. PMC: 2834407. DOI: 10.1093/molehr/gaq002. View

12.

Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H . Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017; 107(6):1380-1386.e1. DOI: 10.1016/j.fertnstert.2017.04.011. View

13.

Locati M, Curtale G, Mantovani A . Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2019; 15:123-147. PMC: 7176483. DOI: 10.1146/annurev-pathmechdis-012418-012718. View

14.

Huang J, Chen P, Xiang Y, Liang Q, Wu T, Liu J . Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells. Int Immunopharmacol. 2022; 107:108717. DOI: 10.1016/j.intimp.2022.108717. View

15.

Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska A . Chronic Low Grade Inflammation in Pathogenesis of PCOS. Int J Mol Sci. 2021; 22(7). PMC: 8038770. DOI: 10.3390/ijms22073789. View

16.

Tannus S, Burke Y, Kol S . Treatment strategies for the infertile polycystic ovary syndrome patient. Womens Health (Lond). 2015; 11(6):901-12. DOI: 10.2217/whe.15.40. View

17.

Kim J, Mahapatra C, Hong J, Kim M, Leong K, Kim H . Functional Recovery of Contused Spinal Cord in Rat with the Injection of Optimal-Dosed Cerium Oxide Nanoparticles. Adv Sci (Weinh). 2017; 4(10):1700034. PMC: 5644223. DOI: 10.1002/advs.201700034. View

18.

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Franks S, Gambineri A . The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014; 171(4):P1-29. DOI: 10.1530/EJE-14-0253. View

19.

Geng X, Zhao J, Huang J, Li S, Chu W, Wang W . lnc-MAP3K13-7:1 Inhibits Ovarian GC Proliferation in PCOS via DNMT1 Downregulation-Mediated CDKN1A Promoter Hypomethylation. Mol Ther. 2020; 29(3):1279-1293. PMC: 7934583. DOI: 10.1016/j.ymthe.2020.11.018. View

20.

Wu R, Van der Hoek K, Ryan N, Norman R, Robker R . Macrophage contributions to ovarian function. Hum Reprod Update. 2004; 10(2):119-33. DOI: 10.1093/humupd/dmh011. View